NEW YORK, Feb. 27, 2018 -- Global Chronic Idiopathic Constipation (CIC) Drugs Market is estimated to reach $2.96 billion by 2024 Says, Profshare Market Research; growing at a CAGR of 6.6% between 2016 and 2024.If the constipation happens chronically with an unidentifiable cause it is known as Chronic Idiopathic Constipation (CIC). The word “Idiopathic” means the cause is not known. Increasing awareness and widespread presence of idiopathic constipation are the key factors for growth of CIC drugs market. Currently CIC drugs market has huge opportunity for research and development.
Depending on type of drugs, global CIC drugs market is segmented into Lubiprostone, Linaclotide and others. Currently Lubiprostone drug segment dominates the market. But, due to its lower efficacy in comparison with others, patent loss and growing competition from Linaclotide, Lubiprostone will lose its dominance in the upcoming future. Depending on prescription types it is subdivided into prescribed drugs and over the counter drugs. After analysing the symptoms also, constipation is not considered as a disease but a condition, side effect or syndrome. Usually patients avoid to visit doctors to address the issue. Therefore approximately 65% of the CIC drugs market is covered by over the counter drugs. The top players of CIC drugs market are Actavis, Chugai Pharmaceutical, Ferring International Center S.A., Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding AG, Sanofi, Bayer AG, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc, Ironwood Pharmaceuticals and Progenics Pharmaceuticals.
Get Free Sample: https://www.profsharemarketresearch.com/sample/chronic-idiopathic-constipation-cic-drugs-market-sample/
Global Chronic Idiopathic Constipation (CIC) Drugs Market: End Users/Application Analysis
- Hospitals & Clinics
- Ambulatory Surgical Centres
- Long Term Care Centres
Global Chronic Idiopathic Constipation (CIC) Drugs Market: Product Type
- Lubiprostone
- Linaclotide
Report Enquiry: https://www.profsharemarketresearch.com/enquiry/chronic-idiopathic-constipation-cic-drugs-market-enquiry/
Global Chronic Idiopathic Constipation (CIC) Drugs Market: Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Chronic Idiopathic Constipation (CIC) Drugs:
- Actavis
- Chugai Pharmaceutical
- Ferring International Center S.A.
- Synergy Pharmaceuticals
- Pfizer
- GlaxoSmithKline
- Roche Holding AG
- Sanofi
- Bayer AG
- Salix Pharmaceuticals Ltd
- Sucampo Pharmaceuticals Inc
- Ironwood Pharmaceuticals
- Progenics Pharmaceuticals
Buy Report: https://www.profsharemarketresearch.com/buy/chronic-idiopathic-constipation-cic-drugs-market-buy-su/
Contact Us:
Mia Cox,
Email- [email protected]
Tel- 1-877-797-7295
www.profsharemarketresearch.com


Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
ADNOC Gas Targets Up to $4B Profit in 2026
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results
US Judge Dismisses Gautam Adani Criminal Charges
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 



